| Annual · values | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — |
| EBITDA Margin | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Current Ratio | — | — | — | — | — | — |
| Quick Ratio | — | — | — | — | — | — |
| Debt / Equity | -0.01 | 0.00 | 0.02 | 0.02 | 0.01 | 0.03 |
| ROE | 1734.41% | -74.17% | -46.25% | -33.94% | -84.54% | -221.94% |
| ROA | -6670.82% | -70.22% | -42.05% | -30.91% | -70.51% | -146.74% |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book Value / Share | -0.25 | 4.05 | 7.28 | 244.86 | 215.85 | 312.25 |
Check-Cap Ltd. is a pioneering healthcare technology company specializing in the development of innovative screening solutions for colorectal cancer. The company is renowned for its advanced capsule-based screening platform designed to detect polyps and abnormal growths in the colon. Unlike traditional methods, the Check-Cap screening platform does not require bowel preparation, thus making it a more patient-friendly alternative. Check-Cap is continuing to make strides in the healthcare industry by providing a non-invasive, radiation-free screening method, aiming to increase participation rates in colorectal cancer screening. By focusing on early detection and patient compliance, Check-Cap plays a vital role in the preventive care segment of the medical field, potentially improving patient outcomes and reducing healthcare costs associated with late-stage colorectal cancer diagnosis. Its groundbreaking technology is of significant interest to healthcare providers and regulators seeking efficient, patient-centered diagnostic solutions, highlighting its significance in the ongoing efforts to combat a major health concern worldwide.